Polylactic acid (PLA) is a biodegradable polymer with decades of clinical use. For procurement teams evaluating PLA-based supplies, the first question is biocompatibility: how the material behaves in contact with the body, and what evidence supports its safe use.
What Biocompatibility Means for PLA
Biocompatibility describes how a material behaves when it contacts living tissue. A biocompatible material performs its intended function without provoking a harmful local or systemic response — no persistent inflammation, no toxicity, no immune rejection. Polylactic acid (PLA) has met this standard in humans for decades. Surgeons have used PLA-based sutures, drug delivery systems, and bone fixation devices since the 1970s, giving it one of the longer clinical track records among biodegradable polymers.
ISO 10993 Testing Framework
ISO 10993 is the international standard family for evaluating the biological safety of medical devices. ISO 10993-1 sets the overall framework: a risk-based approach in which the manufacturer assesses the device’s intended use, contact duration, and body contact type, then selects the relevant tests. The core battery for PLA materials typically includes:
- ISO 10993-5: cytotoxicity — does the material or its extracts damage living cells in culture?
- ISO 10993-10: skin sensitization and irritation — does it trigger allergic or irritant reactions?
- ISO 10993-11: systemic toxicity — are there effects after absorption into the body?
- ISO 10993-3: genotoxicity — any damage to genetic material?
- ISO 10993-6: implantation — local tissue response after surgical implantation.
PLA passes these tests routinely. Its degradation products are mild, its extracts are non-cytotoxic at clinically relevant concentrations, and decades of implantation studies show a controlled, well-tolerated tissue response.
PLA’s Safety Track Record
PLA’s safety rests on its degradation chemistry. In the body, PLA hydrolyzes into L-lactic acid, a natural metabolite that the human body processes through the Krebs cycle and excretes as carbon dioxide and water. This is the same molecule produced during normal exercise metabolism.
Regulators have cleared numerous PLA and PLGA (poly(lactic-co-glycolic acid)) products. Vicryl sutures (polyglactin 910, a PLA/PGA copolymer) have been used worldwide since the 1970s. Lupron Depot, a PLGA microsphere formulation, has delivered controlled-release therapy for decades. PLLA (poly-L-lactic acid) interference screws and dermal fillers hold FDA clearance and Health Canada approval. This regulatory history means the toxicological profile of PLA is among the most thoroughly characterized of any bioresorbable polymer.
PLA vs PHA vs PGA Safety Comparison
Buyers comparing biodegradable polymers should look first at degradation products. PLA breaks down to L-lactic acid; PHA (polyhydroxyalkanoates) degrades to 3-hydroxybutyrate, another natural metabolite; PGA (polyglycolic acid) degrades to glycolic acid.
The difference that matters clinically is local pH. PGA and PLGA release acidic byproducts more rapidly, and acidic microenvironments at the implant site are a documented concern — they can accelerate degradation in a feedback loop and, in some cases, contribute to sterile sinus formation or delayed healing. PLA degrades more slowly, with a gentler acid release profile. PHA is promising and shows solid in vitro and animal data, but it has far less clinical history in humans than PLA. For procurement teams, that history translates into more predictable regulatory documentation.
What Buyers Should Ask for in Biocompatibility Documentation
When evaluating PLA-based products, request:
- ISO 10993 test summaries or reports covering the applicable endpoints (cytotoxicity, sensitization, irritation)
- Certificates of analysis or conformity for raw PLA resin
- Sterilization validation (method, dose, and effect on material properties)
- Material certificates confirming grade, molecular weight, and additive content
Documentation should match the product’s intended contact. CliniEco’s non-implant PLA products — such as our PLA biodegradable isolation gowns and PLA biodegradable underpads — are skin-contact materials, not implant-grade devices, so their biocompatibility requirements differ from those of resorbable implants. The same material family supports PLA biodegradable waste bags. For a broader look at where PLA fits in medical applications, see our guide on what PLA plastic is and how it is used in healthcare.
Related reading
Frequently Asked Questions
Is PLA safe for medical implants?
Yes. PLA and PLGA have been used in FDA-cleared implants — sutures, screws, and drug delivery microspheres — for decades, supported by ISO 10993 testing and long-term clinical follow-up.
Is PLA toxic?
No. PLA degrades into L-lactic acid, a normal human metabolite cleared through the Krebs cycle. Standard ISO 10993 tests for cytotoxicity, sensitization, and systemic toxicity are passed routinely.
What does ISO 10993 test?
ISO 10993 covers the biological safety of medical devices, including cytotoxicity (10993-5), sensitization and irritation (10993-10), systemic toxicity (10993-11), genotoxicity (10993-3), and implantation response (10993-6).
References: ISO 10993-1:2018, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process; Ramot Y. et al., “Biocompatibility and safety of PLA and its copolymers,” Advanced Drug Delivery Reviews (2016); FDA-cleared PLA/PLGA product records (Vicryl sutures, Lupron Depot, PLLA screws).
Related Reading
Explore more guides in this category:
0 commentaire